LP-005 for paroxysmal nocturnal hemoglobinuria (PNH): extension study
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial is for people who have already completed the Phase 2 study of LP-005 and may continue receiving it. It checks how safe and effective the drug is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the Phase 2 clinical trial of LP-005 (study P10-LP005-02).
- Your doctor must agree that continuing LP-005 is right for you.
- You need to have had the Neisseria meningitidis and Streptococcus pneumoniae vaccines (and get booster shots if needed).
- You must be willing to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
This study is for people with paroxysmal nocturnal hemoglobinuria (PNH) who have already taken the experimental drug HSK39297. It checks the long-term safety of continuing the treatment and makes sure it is still helpful.
This study looks at how well iptacopan works for people with PNH (a condition where red blood cells break down too quickly). It is for adults who have never used certain treatments or who have been on other similar medicines.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This Phase 2 study tests how well and how safely NM8074 works for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not recently received a similar “complement inhibitor” medicine. It may help reduce PNH-related blood cell breakdown and anemia, and it will closely monitor side effects.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.